Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

— YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitability — Open-label portion of the pivotal Phase 3 CYPRESS study ofampreloxetine now complete; topline readout on track for Q1 2026 — Company to host anampreloxetine focused virtual Key Opinion Leader (KOL) event for […]

Harmonic to Participate in the 6th Annual Needham Tech Week Conference

Harmonic (NASDAQ: HLIT) today announced that Walter Jankovic, CFO of Harmonic,will host investor meetings at the 6th Annual Needham Tech Week Conference in New York, NY, on Thursday, November 20, 2025. https://mma.prnewswire.com/media/455698/HARMONIC_Inc_logo.jpg For more information, please contact your Needham representative. About Harmonic Inc. Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

— Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review — Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted — Commercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA

Federal Realty Appoints Joseph D. Fisher to Board of Trustees

Seasoned REIT Executive Brings Deep Operating & Financial Expertise to Support Federal's Long-Term Growth Strategy Federal Realty Investment Trust(NYSE:FRT) today announced the appointment of Joseph D. Fisher to its Board of Trustees, effective January 1, 2026. Mr.Fisher will serve on the Board's Audit and Compensation and Human Capital Management Committees. https://mma.prnewswire.com/media/2818862/Joseph_D__Fisher.jpg Mr.Fisher, 46, brings over

Compass Makes Giving Back to Local Communities Easier

New Compass Cares integration allows Compass real estate professionals to support local causes directly through the Compass platform with every transaction Compass real estate professionals can now make donations to Compass Cares, the company's charitable organization, directly through the Compass platform, just in time for the season of giving. With this new feature, every time

Stagwell (STGW) Announces November and December Investor Conference Schedule

Stagwell Inc. (NASDAQ:STGW), the challenger network built to transform marketing, today announced its participation in six upcoming investor conferences in November and December 2025. Representatives from Stagwell's management team will be available for 1×1 and small group meetings at each. — November 17: Seaport 3rd Annual Digital Media & Advertising Conference (Virtual) — November 19:

Blue Owl to Present at The Citizens Financial Services Conference

Blue Owl Capital Inc. (NYSE: OWL) (“Blue Owl”) today announced that Marc Lipschultz, co-CEO, will present at The Citizens Financial Services Conferenceon Tuesday, November 18, 2025 at 12pm ET. A live webcast of the presentation will be available on the Shareholders section of Blue Owl's website at www.ir.blueowl.com. For those unable to listen to the

Red Robin Gourmet Burgers, Inc. Reports Results for the Fiscal Third Quarter Ended October 5, 2025

Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) (“Red Robin” or the “Company”), a full-service restaurant chain serving an innovative selection of high-quality gourmet burgers in a family-friendly atmosphere, today reported financial results for the fiscal third quarter ended October 5, 2025. Highlightsfor the Fiscal Third Quarter of 2025, Compared to the Fiscal Third Quarter of

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated. https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg This Phase 2 signal-seeking study enrolled 73 adult patients with a diagnosis

SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/1503420/SenesTech_Logo.jpg Q3

Scroll to Top